Bevacizumab antibody binds vascular endothelial growth factor (VEGF) inhibiting blood vessels growth, avoiding tumours expansion. During its production, its purification is performed using protein-A affinity chromatography, which highly increases its overall production cost. In this work, an affinity-based precipitation has been designed with a trivalent peptide corresponding to the VEGF epitope that interacts with bevacizumab.
Trivalent Peptide Design for Bevacizumab Salt-Induced Affinity Precipitation / Eloy, J.A., Barredo-Vacchelli, G.R., Rodríguez, J.A., Richichi, B., Marradi, M., Camperi, S.A.. - ELETTRONICO. - (2026), pp. 0-0. (6th International Congress on Health Innovation—INOVATEC 2025 ) [10.3390/proceedings2026137058].
Trivalent Peptide Design for Bevacizumab Salt-Induced Affinity Precipitation
Richichi, Barbara;Marradi, Marco;
2026
Abstract
Bevacizumab antibody binds vascular endothelial growth factor (VEGF) inhibiting blood vessels growth, avoiding tumours expansion. During its production, its purification is performed using protein-A affinity chromatography, which highly increases its overall production cost. In this work, an affinity-based precipitation has been designed with a trivalent peptide corresponding to the VEGF epitope that interacts with bevacizumab.
| File | Dimensione | Formato | |
|---|---|---|---|
|
proceedings-137-00058.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
124.03 kB
Formato
Adobe PDF
|
124.03 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
